ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) and Elekta (OTCMKTS:EKTAY – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.
Earnings and Valuation
This table compares ClearPoint Neuro and Elekta”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ClearPoint Neuro | $40.61 million | 8.45 | -$25.54 million | ($1.01) | -11.33 |
| Elekta | $1.71 billion | 1.37 | $22.37 million | ($0.01) | -636.00 |
Institutional and Insider Ownership
30.1% of ClearPoint Neuro shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Comparatively, 41.3% of Elekta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Elekta has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for ClearPoint Neuro and Elekta, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ClearPoint Neuro | 1 | 0 | 2 | 0 | 2.33 |
| Elekta | 1 | 2 | 0 | 0 | 1.67 |
ClearPoint Neuro currently has a consensus price target of $18.00, indicating a potential upside of 57.34%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, research analysts clearly believe ClearPoint Neuro is more favorable than Elekta.
Profitability
This table compares ClearPoint Neuro and Elekta’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ClearPoint Neuro | -71.57% | -140.96% | -36.98% |
| Elekta | -0.08% | 12.84% | 3.88% |
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
About Elekta
-logo-1200x675.png?v=20240604134456){kind=logo}
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Receive News & Ratings for ClearPoint Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ClearPoint Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
